We would love to hear your thoughts about our site and services, please take our survey here.
Docdaneeka, I understand what you are saying and I usually would not respond to most of the noise however reading Anybe4's post I just thought it was unfair that the company we are invested in and the people running the company were being described with terms such as "no urgency" and "sluggish" so I thought it warranted a response in defence of those who are moving mountains to save lives globally and earn us some cash in the process. Also bit of a quiet Friday night for me.
ATB to you Doc
Andybe4, the difference between Pfizer and Synairgen trials is that Pfizer's trial was under a rolling submission, data was being fed to regulators as it came. The whole world and every governmental health agency had hawk eyes on Pfizer and AstraZeneca due to the global demand and urgency for vaccines.
"I am beginning to see the trend by Synairgen that there is no urgency in deploying this drug at all." quite a wild statement.
Do you think the team are sat around eating KP peanuts and playing twister in the offices with RM walking in "so then, anyone fancy trying to get our drug approved that we been developing for over 15 years?" they all laugh "nah it can wait another couple more months" they go on to drag RM into a fresh twister round.
Or do you think the team are working endlessly and tirelessly with all parties involved to get the P3 readout and EUA submission bang on the money as they really could not afford to have this go tits up at this stage.
As you can see from sleuthing and research from many posters across different platforms there is so much going on behind the scenes. Prime example yesterday nobody had a clue about Synairgen being first client for Ray Jordan's consultancy firm Putnam Insights. This must have been in the works for months, who knows what other nuggets are yet to come. PS thanks Brand for that find.
If you have researched the BoDs you should be aware that they are all highly credible and add great value to the company with their vast experience from being in senior positions in big pharma companies, describing the efforts of the company with terms such as "sluggish" is imo unfair.
AIMO best of luck all, have a great weekend. Not much longer now.
FWIW I just signed up to ADVFN to have a gander and I can see that the user who started the thread Northern66 has updated at 15:37 with the following:
"Thanks for the feedback. He is a very reliable source when it comes to biotechs and he is heavily invested here.
I did call the harbour hotel, they said they have had many calls and all they can say is that the room is booked. No names given."
https://www.cell.com/trends/immunology/current#fullCover
In addition to other themes, this issue comprises reviews and opinion articles on human immune responses against infections (such as SARS-CoV-2), including aspects of evolution, natural resistance, and vaccination.
As an example, depicted here, are interferons and SARS-CoV-2 caught in an epic battle to ‘knock out’ each other. The SARS-CoV-2 character appears on a background of SARS-CoV-2-infected cells stained for the nucleocapsid protein (red), and the interferon character appears on a background of healthy human airway cells in which the nuclei are stained in blue (see also Trends in Immunology 2021;42(12):1069–1072). Image credit: Arinjay Banerjee, Kaushal Baid, and Ayantika Roy. Cover design: Catarina Sacristán.
Courtesy of @1985muenchen on Twitter.
Planning Committee Member: Richard Hennings - CCO at Synairgen Research ltd
Hosted by the American Thoracic Society, the 2022 Respiratory Innovation Summit will unite the innovators, investors, clinicians and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways.
Event Date: May 13-18
Application Deadline: Feb. 25, 2022
https://conference.thoracic.org/program/ris/index.php
To me it seems like the company had many things lined up and they were awaiting data to be unblinded. Seeing positive results RM has given the green light on the below to go public/live, if the data was a dud none of the below would have been given the green light to go live as RM has shown nothing but professionalism and integrity so far.
- Ashfield Engage partnership
- New website
- 5 New Senior US based positions opened
- 3 New videos
AIMO, best of luck all not much longer.
Interested in joining a fast-growing, collaborative and supportive team driven to make a difference for people with #COVID19? Then get in touch! https://bit.ly/3KxlrUy
#Synairgen #hiring #nowhiring #biotechcareers
"We're seeking feedback from the biopharmaceutical industry focused on developing, establishing and improving #MedicalCountermeasure manufacturing capabilities to help prepare for and respond to emerging & ongoing #pandemic threats. See the RFI for details.
https://www.medicalcountermeasures.gov/barda/influenza-and-emerging-infectious-diseases/coronavirus/pharmaceutical-manufacturing-in-america#workshop-registration
Jwd222,
Yes, Synairgen are a relatively small company but the companies they have partnered with are huge within the pharma industry and are the same companies other big pharma cos use.
Begin by looking in to the below companies.
Akron Biotech
Aerogen
Catalent
Thermo Fisher
Did you really think SNG001 was going to be produced on site in Southampton?
"In this paper, we present the evidence that vaccination, unlike natural infection, induces a profound impairment in type I interferon signaling, which has diverse adverse consequences to human health."
Apologies if posted already. Published 21st Jan 2022.
shorturl.at/jCIJ8
Hi Andy, thanks, did you see one of the authors of the pre-print comments on twitter?
https://twitter.com/Friedemann1/status/1485026595639287817?s=20
https://twitter.com/Friedemann1/status/1485037292075073537?s=20
https://twitter.com/Friedemann1/status/1485044767834714117?s=20